Hoppa till innehållet

OMXSPI+1,18%

S&P 500+0,16%

FTSE 100+0,05%

DAX+0,35%

NIKKEI+0,73%
Redeye: Hansa Biopharma Q1 - Improved European launch support

Redeye updates its outlook on Hansa Biopharma, anticipating improved launch support during 2024 and pipeline progress over the next 12 months. A growing number of countries and centres have added to the European launch, and the Eurotransplant program is also resulting in more patients using Idefirix regularly. Our Base Case remains SEK120 with a Bull Case of SEK220 and a Bear Case of SEK15.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Hansa Biopharma Q1 - Improved European launch support

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera